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Summary.-Extracts of ovine squamous-cell carcinoma (OSCC) prepared by dif-
ferent procedures, were injected at varying concentrations into 184 tumour-bearing
sheep. At a total protein of0X5 mg and greater, there was significant enhancement and
metastasis in all 120 sheep examined. Extracts of OSCC containing less than 0.5 mg
protein, or of human squamous-cell carcinoma and normal sheep skin containing
high levels of protein, had no effect on subsequent tumour development. Extracts of
foetal sheep skin at the 3mg-protein level produced significant enhancement and
metastasis. The degree of enhancement was inversely proportional to the develop-
mental stage of the tumour at the time of treatment.
WHILST immunotherapy of neoplastic
disease has been practised for many de-
cades (Muggia, 1977) only of recent years
has the immunological basis of such im-
munotherapy been clarified (Woodruff,
1964; Baldwin and Price, 1976). Bluming
(1975), Nelson (1974) and Baldwin and
Price (1976) have described the associa-
tion of tumour-associated antigens with
partial immunity to individual tumours,
and have outlined the association of such
antigens with immunity-blocking factors.
Kahan (1973) and Kahan and Pellis (1975)
have described the biological criteria in the
use of fresh subcellular tumour extracts
for specific immunoprotection, and as
therapeutics.
Successful immunotherapy trials have
been reported in haemopoietic disease of
humans and rodents (Mathe, 1971; Parr
1972), in bovine squamous-cell carcinoma
(van Kampen et al., 1973; Spradbrow et
al., 1977), and in some solid tumours of
humans (Hughes et al., 1970). The need
for careful evaluation of immunothera-
peutic treatment has beenshownbySprad-
brow et al. (1977) who obtained regression
of bovine squamous-cell carcinoma with
single treatments, but enhancement with
multiple treatments.
Ovine squamous-cell carcinoma (OSCC)
is a relatively common lesioninthetropical
zones of Australia, occurring as a solar
keratosis in an average of 300 of sheep
(Ladds and Entwistle, 1977). The gross
and histopathological features of this
tumour have been described in detail
(Lloyd, 1961; Ladds and Entwistle, 1977).
The present communication describes
the results of immunotherapy of OSCC,
using a range of tumour extracts with
varying total protein contents.
MATERIALS AND METHODS
Preparation of antigen (tumour extracts).-
Biopsied tumours were sliced into 5mm sec-
tions, and held at 4°C in phosphate-buffered
saline, pH 7-2 (PBS) for up to 4 h before
processing. Tumour slices were trinmmed of
dead tissue and skin, and were finely minced.
The suspension was then forced through a 60-
mesh stainless-steel sieve and the cell suspen-
sions obtained were tested by trypan-blue
exclusion for viability. In all cases cell via-
bility ranged from 75%o to 90o%.
Cell suspensions were then snap-frozen in
liquid N2 to form a cake, which was pulver-ENHANCEMENT OF METASTASIS BY IMMUNOTHERAPY
ized in a locally manufactured stainless-steel
tissue homogenizer. Powdered tissues were
then treated as below.
(a) Ultrasonication (u/s TA).-One part of
tumour tissue in 4 parts of chilled PBS was
ultrasonicated at 20-25 kV/s for 4 min in an
MSE 100-watt ultrasonic disintegrator. Soni-
cated suspensions were filtered through cotton
wool and 60-mesh copper sieves. These ex-
tracts were frozen and thawed twice before
use.
(b) 2m NaCI tumour extracts (2M NaCI TA).
-One part of powdered tumour and 4 parts
of 2M NaCl were stirred at 4°C for 16 h, and
then clarified by centrifugation at 4500 g for
20 min. The supernatant fluids were then
dialysed x3 against 200 volumes of PBS at
4°C over 36 h. The dialysate was then centri-
fuged at 70,000 g for 3 h in a refrigerated cen-
trifuge, the supernatant, representing soluble
extract, being stored at -20°C before use.
(c) 3MKCltumour extracts (3MKCO TA).-
The procedure used was a modified version of
that described by Kahan and Pellis (1975) as
outlined for 2M NaCl extracts above.
(d) DNA-enriched tumour extracts.-A
modification of the technique described by
Kirby (1957) was used. One part ofpowdered
tumourwas stirred in 4 volumes of6%sodium
p-amino-salicylate, whilst 5 volumes of 90%
phenol (w/w) was quicklyadded. Afterstirring
at 4°C for 2 h, the mixture was centrifuged at
2500 g for 30 min, and the supernatant col-
lected. This was thendialysed and centrifuged
at 70,000 g for 3 h as described above.
(e) Saline-phenol extracts.-Slight modifi-
cation of the technique described by Sprad-
brow et al. (1977) was used. One part of
powdered tumour was minced with 2 parts of
0415M NaCl and 2 parts of freshly distilled
phenol. After clarification at 70,000 g for 30
min, the aqueous phase and interface were
pooled, and dialysed as above (or ether
extracted) to remove excess phenol. Finally
high-speed centrifugation was carried out as
above.
Control antigens were prepared in a similar
manner to the above.
Antigen administration.-Protein concen-
tration of inocula was adjusted as required,
using an SP 800A UV spectrophotometer
(UNICAM) at 280 nm, and results were
checked by the technique described by Lowry
et al. (1951). Extracts were diluted with PBS
to required concentration. Where complete
Freund's adjuvant (CFA) was used, the ex-
tracts were first concentrated to half the
original volume by dialysis against polyethy-
lene glycol at 4°C to maintain constancy of
inoculum volume. All extractswereinoculated
i.m. in the thigh.
Experimental animals.-A total of 241
sheep were used as indicated in Table I. All
sheep were between 5 and 8 years old, and
both sexes were represented in equal propor-
tions in each group. All sheep had tumour
lesions classified on development and volume
as Stage II or Stage III tumours (mean
tumour volume of 15 cm3 and 30 cm3 respec-
tively). Due to environmental stress, 28 sheep
TABLE L.-Numbers of tumour-bearing
sheep used in testing extracts
Experimental ir
group
Ultrasonicated
tumour antigen
2M NaCl tumour
extract (TA)
3M KCI TA
DNA-enriched TA
0* 15M saline-
phenol TA
2M saline-phenol TA
Subtotal
0
- 15M saline-
phenol extract
of normal
sheep skin
3M KCI extract
of normal
sheep skin
3M KCI extract of
foetal sheep skin
DNA-enriched
extract of
human SCC
Complete Freund's
adjuvant alone
(3 ml)
Subtotal
Uninoculated
control group
Protein
njected
(mg)
3 0
3 0
3 0
50*0
25*0
0-5
001
3 0
3 0
0O5
001
3 0
0 5
001
No. of
sheep
in
group
16* (8/8)t
30* (15/15)
30* (15/15)
6 (3/3)
6 (3/3)
6 (3/3)
6 (3/3)
16* (8/8)
27 (14/13)
6 (3/3)
6 (3/3)
17 (8/9)
6 (3/3)
6 (3/3)
184 (92/92)
3 *0 8 (4/4)
3 0 8 (4/4)
3 *0 8 (4/4)
3 *0 4 (2/2)
7 (4/3)
35 (18/17)
22 (11/11)
No. of
sheep
"lost"
during
experiment
2
5
3
1
1
0
1
2
2
0
1
2
1
1
22
1
1
1
1
0
4
* 50% of each group received antigen mixed with
complete Freund's adjuvant.
t No. in Stage II/No. in Stage III.
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were lost from all groups during the 7 months
experimental period.
Animals on test were observed at 2, 4, 8,
16, 24 and 28 weeks post injection (p.i.) and
were then killed for autopsy. At each exami-
nation tumours were photographed and
measured, and blood samples were taken for
subsequent serology. Biopsy samples or tis-
sues taken at necropsy, were fixed in 10%
buffered formalin, embedded in paraffin and
stained with haematoxylin and eosin (H. and
E.), and Ayoub-Shklar technique for keratin
and prekeratin (Luna, 1968).
Measurement of tumour volume.-Tumour
volume (cm3) was calculated in each case by
caliper measurement (Mitutoyo Co., Japan).
This was done by either measurement of the
base area ofthe tumour multiplied by height
in cm for conical tumours, or estimation of
the volume of non-conical tumours by
measuring the central width in two constant
planes and multiplying by the depth. Photo-
graphy of each tumour at the time of exami-
nation enabled a rough check on volume from
the photographs.
Tumour growth was calculated from the
following formula:
Percentage (%) oftumour growth=
Tumour volume _ Tumour volume
after treatment before treatment x 100
Tumour volume before treatment
Statistical analysis.-Percentages oftumour
growth were transformed to logarithms and
analysedbya2-way (stage X antigen) analysis
of variance. Differences between comparisons
were considered significant if P<0 05.
Throughout the text, means ±s.e. are quoted.
RESULTS
Control groups
In the 22 OSCC sheep which received no
inoculation, the tumours developed slowly
and regularly over the 24-week observa-
tion period (88 4+3 9%). In the control
groups receiving 0 15M saline-phenol or
3M KCI extracts containing 3 mg of total
protein from normal sheep skin, from
DNA-enriched extract of human squa-
mous-cell carcinoma, or of CFA alone,
there was no significant difference in
growth from the uninoculated group (P>
0.05, Fig. 1). The group inoculated with
3M KCI extract of ovine foetal skin con-
taining 3 mg total protein showed signifi-
cantenhancementofgrowth incomparison
to other controls (P<0 0005, Fig. 1).
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FIG. 1. Tumour growth-rate in uninoculated
control group and antigen control groups
inoculated i.m. with 3-0 mg of protein.
* Uninoculated control group 22 sheep.
* Complete Freund's adjuvant (3 ml)
alone-7 sheep. 0 3M KCI extract of nor-
mal sheep skin 8 sheep. * 3M KCI extract
of foetal sheep skin 8 sheep. D1 0-15M
saline-phenol extract of normal sheep skin
-8 sheep. 0 DNA-enriched extract of
human squamous-cell carcinoma-4 sheep.
Each point represents a mean. P values
were calculated from data at 8 weeks p.i.
Low concentrations ofprotein
Groups inoculated with 0 01 mg of
OSCC protein extracted with 3M KCI or
saline-phenol (015M and 2M) showed no
significant differences in tumour develop-
ment from the uninoculated group over
the 24 weeks of observation (P>0 05).
Groups inoculated with 0 5 mg of protein
in the same type of extracts showed ob-
vious enhancement of tumour growth at
8 weeks p.i. (154.8±8.3%, 166.0+8-8%,
195.3±11-5%) at significance levels of P
<0 0005. Fig. 2 shows the results of in-
jection of 0 01 mg and 0 5 mg of OSCC
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Fi(.. 2. Tumour growth-rate in groups of 6
OSCC sheep inoculated i.m. with varying
amounts of tumour protein. No CFA was
used. A 50 mg in 3MKCl tumour extract.
O 25 mg in 3M KCI tumour extract. A
0-5 mg in 3M KCI tumour extract. 0 0-01
mg in 3M KCI tumour extract. * uIn-
inoculated control group 22 sheep. P
values were calculated from data at 8
weeks p.i.
protein obtained by extraction with 3M
KCI.
Median concentrations ofprotein
For this test all the extract types de-
scribed were used, and protein content of
all OSCC inocula was 3 mg. All extract
types were regularly associated with sig-
nificant enhancement at this protein
concentration (Figs. 3 and 4).
Such enhancement first became evident
WEEKS AFTER INJECTION
FiGe. 3. Tumour growth-rates in OSCC
groups inoculated i.m. with 3-0 mg of tum-
our protein. A Ultrasonicated tumour ex-
tract (no CFA)-8 sheep. A Ultrasonicated
tumour extract with CFA 8 sheep. -
DNA-enriched tumour extract (no CFA)
8 sheep. 0 DNA-enriched tumour extract
with CFA 8 sheep. * Uninoculated
control group 22 sheep. P values were
determined from data at 8 weeks p.i.
at 4 weeks p.i., maximal enhancement
occurring between 8 and 16 weeks p.i.
After 16 weeks p.i., the rate of tumour
growth in all inoculated groups was com-
parable to that in uninoculated control
sheep. Calculated at 8 weeks p.i. the great-
est enhancement was observed inthe group
inoculated with 3M KCI TA (5061 +
18*7 0), whilstthe lowest enhancement was
evident in the ultrasonicated TA group
(2137±13-3%). Significant differences
(P<0'05-<0 001) in enhancement were
noted between groups inoculated with
3M KCI TA, 2M NaCl TA and saline-phenol
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FIG. 4. Tumour growth-rates in OSCC groups
inoculated i.m. with 3 0 mg of tumour
protein. * * 3M KCI tumour extract
(no CFA) 15 sheep. O 3mI KCI tumour
extract with CFA 15 sheep. A 2M NaCl
tumour extract (no CFA) 15 sheep. A
2M NaCl tumour extract with CFA 15
sheep. 0 0-15M saline-phenol tumour
extract-27 sheep. 0 2m saline-phenol
tumour extract 17 sheep. *... a Un-
inoculated control group-22 sheep. P
values were determined from data at 8
weeks p.i.
(0-15M and2M) tumourextracts (Fig. 4), but
there was no significant difference between
groups inoculated with 015M saline-
phenol TA or 2M saline-phenol TA (P>
0 05, Fig. 4). The addition of CFA to
inocula showed significant effect only in
the ultrasonicated TA group, where it was
associated with a decrease in enhancement
at 8 weeks p.i. (P<0 001, Fig. 3).
High concentrations ofprotein
Groups inoculated with 25 or 50 mg of
protein extracted with 3M KCl showed
significant increases in tumour enhance-
ment over groups receiving 3 mg of pro-
tein in the same type of extract (P<0 05,
Fig. 2).
Repeat injections
Three animals in each group inoculated
with median doses of protein in ultrasoni-
cated TA, 2M NaCl TA and 3Ai KCI TA
(without CFA) were reinoculated at 16
weeks p.i., with the same volume and
concentration ofextract as originally used.
No significant increase in growth occurred
overthe subsequent 8 weeks ofobservation
in comparison to inoculated controls or
single-injected animals.
Enhancement in Stages II and III
Comparisons of tumour enhancement
ratio of Stage II and Stage III tumours
were made in each group at 8 weeks p.i.
(Fig. 5). All groups inoculated. with tu-
mour antigen amounts of 0-5 mg or more
protein showedsignificantly moreenhance-
ment of Stage II than of Stage III
tumours, significance levels ranging from
P<0 025-<0 0005. Nodifferencesbetween
growth rates of Stage II and Stage III
were noted in the uninoculated group,
groups injected with 3M KCI extract of
normal sheep skin, DNA-enriched human
squamous-cell carcinoma extract, or CFA
alone.
Macroscopic and microscopic observrations
Macroscopic changes in an enhanced
tumour are shown in Fig. 6, and distribu-
tion of metastases in Table II. The un-
inoculated control group showed 15% of
cases with metastases to local lymph nodes
only. Among the antigen control groups
similar findings were made, except that in
the case of 3M KCI extracts of foetal sheep
skin 28.600 of cases showed metastases to
local lymph nodes only. There was a mark-
ed increase in gross metastases in the
groups inoculated with OSCC tumour anti-
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Flm. 5. Comparison of tumour growth-rate between Stage II and Stage III tumours in the groups
inoculatecl with tumour antigen containing 3 mg total protein and control groups, at 8 weeks
p.i. * 3mI KCI extract of normal sheep skin. Z Mean±s.d. Stage II. D Mean±s.d. Stage III.
gens at total protein levels of 5 mg or
more, local lymphnode involvement
averaging 62.5% and lung involvement
830,/. The greatest degree of metastasis
was noted in the groups inoculated with
3M KCI extracts containing more than
05 mg of protein. After injection of tu-
mourprotein at anyleveltested, biopsies of
tumours taken at 8 weeks and 28 weeks
p.i., showed a greater infiltration with
lymphocytes, plasma cells and macro-
phages than did tumours from uninocu-
lated animals. Mitotic figures were much
more evident in enhanced tumours (Figs.
7 and 8).
Study of lymphatic vessels in dermis
and subcutis of neoplastic skin, parotid
lymph nodes, mandibular lymph nodes
and lung were made in all cases. Frequent
involvement of lymphatic vessels with
characteristic tumour were noted in en-
hanced animals where spread to local
lymph nodes occurred (Table II).
DISCUSSION
The purpose of this preliminary work
was to attempt duplication with OSCC of
the successful trials of van Kampen et al.
(1973), and subsequently of Spradbrow et
al. (1977) in immunotherapy of bovine
squamous-cell carcinoma.
Although van Kampen et al. (1973) gave
nodetailsoftumour-extraction procedures,
other than a reference to "an adequate
concentration of saline-phenol extract of
fresh tumour tissue", reference is made to
the extract as a nucleoprotein treatment.
Spradbrow et al. (1977) used either 015M
saline-phenol, or IM saline-phenol ex-
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Fie. 6.-Enhancement of ovine squamous-cell carcinoma (OSCC) after injection of 3 -0 mg of tumour protein (3M KCI extract). A: Tumour lesion before 3M KCI tumour extract injection. B: The same lesion 8 weeks after 3M KCI tumour extract treatment, showing enhancement of tumour growth.
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FIG. 7.-Histopathological features of OSCC from an uninoculated control group, showing neoplastic
squamous cells invading stroma, few mitosis, keratin formation by neoplastic cells, and a few mono-
nuclear inflammatory cells infiltrating around neoplastic cell nests. H. and E. x 576.
FIG. 8.-Histopathological features of OSCC biopsied at 8 weeks p.i. "immunotherapy" with 3M KCI
tumour extract; showing increase in mitotic figures (arrows) heavy infiltration of plasma cells,
lymphocytes and macrophages. The neoplastic cells appear more invasive than in Fig. 7. H. and E.
x 576.
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TABLE IJ.-Metastases observed in tumour-
bearing sheep necropsied p.i.
Metastastic lesions
recordedt (and %)
Lym-
phatic
vessels
in Local
Experimental No. of primary lymph
group sheep lesions nodes Lung
Ultrasonicated
tumour
antigen 14 2 (14) 7 (50) 0 (0)
2M NaCl TA 25 9 (36) 17 (68) 2 (8)
3M KCI TA 27 11 (41) 23 (85) 4 (15)
DNA-enriched TA 14 0 (0) 6 (43) 0 (0)
0- 15M saline-
phenol TA 25 5 (20) 14 (56) 3 (12)
2M saline-
phenol TA 15 4 (27) 8 (53) 1 (7)
Subtotal (%) 120* 31 (26) 75 (63) 10 (8)
0- 15M saline-
phenol extract
of normal
sheep skin 7 1 (14) 1 (14) 0 (0)
3M KCI extract
of normal
sheep skin 7 0 (0) 1 (14) 0 (0)
3M KCI extract
of foetal sheep
skin 7 1 (14) 2 (29) 0 (0)
DNA-enriched
extract of
human SCC 3 0 (0) 0 (0) 0 (0)
Complete Freund's
adjuvant
alone (3 ml) 7 0 (0) 1 (14) 0 (0)
Subtotal 31 2 (7) 5 (16) 0 (0)
Uninoculated
control group 20 2 (10) 3 (15) 0 (0)
* Only sheep receiving median doses of tumour
protein (3 mg) are considered, to simplify the table.
t Gross and/or microscopic lesions.
tracts successfully, but again gave no de-
tails of any adjustment or calculation of
protein content of preparations.
In the present series of trials there was
an obvious relationship between the pro-
tein content of inocula and their effect on
the tumour. At a level of. 0 01 mg of pro-
tein, no change in tumour development in
comparison to controls occurred. At 0 5
mg protein, enhancement of tumour
occurred, this enhancement increasing
directly with increase in concentration
of protein. Associated with enhance-
ment, there was a parallel increase in
the frequency of metastases in lym-
phatic vessels draining the lesion, in local
lymph nodes and in lung. The extract pre-
paration described by Spradbrow et al.
(1977) gave with OSCC extracts very high
levels of protein which were associated
with enhancement and metastases in
sheep. It would seem that a very different
response to immunotherapy occurs in
bovine squamous-cell carcinoma from that
observed with OSCC.
Whilst there were differences in degree
of enhancement with different types of
extract, this could not be related to the
gross protein content ofthe extract, as all
extracts were adjusted to the same overall
protein levels. OSCC tumour extracts have
been shown to contain quantitatively one
major and 2 minor proteins (Jun, Maguire
and Johnson, unpublished observation). It
is possible that the different types of ex-
traction procedure may give differing pro-
portions of these proteins. It is possible
that one of these proteins at least is a
foetal antigen, as a degree ofenhancement
was noted with extracts of foetal lamb
skin.
As yet, insufficient data are available
to attempt an explanation of the mecha-
nisms involved in enhancement of OSCC
by tumour extracts. Symes (1974) and
Baldwin and Price (1976) associate en-
hancement after immunotherapy with
an increase in circulating antibody/anti-
gen complexes (blocking factors). It is,
however, difficult to believe that the rela-
tively small amounts of protein injected
would be any more efficient in modifying
the immune response than the bulk of
antigen associated with the growing tum-
our. Further work on the mechanism of
enhancement is in progress.
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